

BCCA Protocol Summary for Treatment of Locally Advanced Bladder Cancer with Weekly Cisplatin and Concurrent Radiation

Protocol Code:
Tumour Group:
Contact Physician:

*GUBPWRT
 Genitourinary
 Dr. Kim Chi*

ELIGIBILITY: all of the following

- Transitional or squamous bladder cancer
- Stages T3 or T4 (any NM)
- Requiring radical or palliative radiation
- Unsuitable for either GUAVPG, or GUBP(biweekly cisplatin with radiation)
- Serum creatinine < 140 µmol/L (see Dose Modifications section)

EXCLUSIONS:

- contraindication to cisplatin (e.g. deafness, intolerance to fluid load, neuropathy)
- ECOG status ≥ 3

TESTS:

Baseline and before each treatment (on treatment day or within two previous days, attempt to coordinate with routine radiation therapy tests):

- CBC (with platelets) & diff, creatinine, electrolytes

PREHYDRATION:

1000 mL NS with 20 mEq potassium chloride and 2 g magnesium sulphate over 1 hour, prior to cisplatin

ANTIEMETICS:

As per highly emetogenic protocol

TREATMENT:

Note: Since cisplatin is a radio-sensitizing as well as an active agent, it is to be administered on a day on which radiation therapy is delivered. If radiation therapy is cancelled, do not give cisplatin that day: postpone until radiation therapy resumes.

Drug	Dose	BCCA Administration Guidelines
Cisplatin	40 mg/m ²	IV in 1000 mL NS over 1 hour

Repeat weekly during radiotherapy (max 6 cycles)

DOSE MODIFICATIONS:

ANC ≥ 0.8	Proceed with treatment
ANC < 0.8	Consider dose reduction or delay

Serum creatinine > 140 µmol/L	Delay chemotherapy, recheck in 1 week
Serum creatinine still > 140 µmol/L after one week chemo delay	Discontinue protocol

PRECAUTIONS:

1. **Renal Toxicity:** Nephrotoxicity is common with cisplatin. Encourage oral hydration. Avoid nephrotoxic drugs such as aminoglycosides.
2. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Chris Coppin or tumour group delegate @ (604) 587-4306 with any problems or questions regarding this treatment program.

Date activated: 01 January 2006 (as GUBPW)

Date revised: 1 Oct 2007(protocol code changed)

References:

1. Coppin CML, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996;14:2901-7.
2. Thomas GN. Improved treatment for cervical cancer – concurrent chemotherapy and radiotherapy. New Engl J Med 1999;340:1198-1200.